Shanghai Fosun Pharmaceutical (SHA:600196) obtained a drug registration for monoclonal antibody injection HLX11 from China's drug administrator.
HLX11 is a pertuzumab biosimilar intended to be used in combination with trastuzumab and chemotherapy for the treatment of breast cancer, according to a Wednesday filing with the Shanghai Stock Exchange.
Shares of the pharmaceutical company were down 1% in recent trade
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。